TW200404550A - Cepharospolin formulation for oral use - Google Patents
Cepharospolin formulation for oral use Download PDFInfo
- Publication number
- TW200404550A TW200404550A TW092118481A TW92118481A TW200404550A TW 200404550 A TW200404550 A TW 200404550A TW 092118481 A TW092118481 A TW 092118481A TW 92118481 A TW92118481 A TW 92118481A TW 200404550 A TW200404550 A TW 200404550A
- Authority
- TW
- Taiwan
- Prior art keywords
- cephalosporin
- preparation
- oral
- oral use
- mannitol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
Description
200404550 玖、發明說明: (技術領域) 本發明爲有關改善苦味之經口用頭孢菌素製劑。 (先前技術) 改善藥物苦味之方法已知配合糖類、人工甘味料、糖醇 、酸味料、胺基酸、麩胺酸鹽、香料之方法。但藥物之化 學構造不同則苦味之種類也變化,故對藥物固有苦味找出 呈最適改善效果之配合處方並非容易。 經口用頭孢菌素化合物(尤其酯前藥型頭孢菌素)其化合 物群具有特有之強烈苦味。乾糖漿劑等藥物分散口腔內而 易感苦味之製劑,爲使服用容易,殷望改善苦味之製劑處 方。 (發明內容) 本發明者就經口用頭孢菌素之苦味改善長年反複檢討之 結果,糖醇與草莓香料配合則比從來之處方呈特別優異之 苦味改善效果,終於完成本發明。 本發明爲如下改善苦味之經口用頭孢菌素製劑° (1) 一種經口用頭孢菌素製劑,其特徵爲含有糖醇及草莓 香料。 (2) 如(1 )之經口用頭孢菌素製劑,其中經口用頭孢菌素爲 酯前藥型頭孢菌素° (3) 如(1)之經口用頭孢菌素製劑’其中經口用頭孢菌素爲 選自雪芙波特奇西母普羅期血吉(Cefpodoxime proxetil)、 血佛奇阿母黑期血吉(Cefotiam Hexetil)、雪芙鐵拉母比伯 -6- 200404550 期西路(Cefteram Pivoxil)、雪芙羅奇西母阿苦血吉 (Cefuroxime Acetil)、雪芙也達美多比伯斯西路(Cefetaniet Pivoxil)、雪芙地多連比伯期西路(Cefditoren Pivoxil)及雪 芙卡賓比伯期西路(Cefcapene Pivoxil)之經口用頭孢菌素 製齊U。 (4) 如(1 )之經口用頭孢菌素製劑,其中經口用頭孢菌素爲 雪芙波特奇西母普羅期血吉。 (5) 如(1)〜(4)中任一項之經口用頭孢菌素製劑,其中糖醇 爲選自赤蘚糖醇、木糖醇、甘露糖醇及山梨糖醇。 (6) 如(1)〜(4)中任一項之經口用頭孢菌素製劑,其中糖醇 爲D -甘露糖醇。 (7 )如(1 )〜(6 )中任一項之經口用頭孢菌素製劑,其中製劑 爲選自乾糖漿劑、可嚼錠、口腔內速崩壞錠、舌片劑、散 劑及顆粒劑。 (8) 如(1)〜(6)中任一項之經口用頭孢菌素製劑,其中製劑 爲乾糖漿劑。 (9) 如(1)之經口用頭孢菌素製劑,其中製劑爲含有D_甘露 糖醇及草莓香料之乾糖漿劑。 (10) 如(1)之經口用頭孢菌素製劑,其中製劑爲含有D_甘露 糖醇及草莓香料爲特徵之雪芙波特奇西母普羅期血吉之乾 糖漿劑製劑。 本發明所使用之糖醇只要爲糖之羰基被還原之多價醇則 無特定,例如赤蘚糖醇、木糖醇、甘露糖醇及山梨糖醇。 追些中宜甘露糖醇,最宜爲D _甘露糖醇。 200404550 糖醇之配合量在經口用頭孢菌素製劑中通常宜2 0〜8 0 重量%,最宜3 0〜6 0重量%。用D -甘露糖醇時,宜3 5〜5 0 重量〇/〇 〇 本發明所使用之草莓香料可爲例如草莓微粒、草莓香素 、草莓香粉及草莓香精,宜草莓香素草莓微粒。 草莓香料之配合量在經口用頭孢菌素製劑中通常宜〇. 〇 1 〜5重量%,最宜爲0.05〜2重量%。使用草莓香素時,最 宜爲0.05〜0.1重量%。 本發明使用之經口用頭孢菌素只要爲經口投與有效之化 β 合物則無特定,宜4位羧基以酯保護之酯前藥型頭孢菌素 。頭孢菌素之酯前藥可爲例如,雪芙波特奇西母普羅期血 吉、血佛奇阿母黑期血吉、雪芙鐵拉母比伯期西路、雪芙 羅奇西母阿苦血吉、雪芙也達美多比伯斯西路、雪芙地多 連比伯期西路及雪芙卡賓比伯期西路,最宜爲雪芙波特奇 西母普羅期血吉。 經口用頭孢菌素之配合量在經口用頭孢菌素製劑中通常 宜5〜40重量%,最宜爲5〜15重量%。使用雪芙波特奇西 ® 母普羅期血吉時,最宜爲5〜1 0重量%。 本發明適用之製劑只要爲經口投與製劑則無特定,宜適 用在口腔內藥物分散而易感苦味之製劑,例如乾糖漿劑、 可嚼錠、口腔內速崩壞錠、舌片劑、散劑或顆粒劑等。尤 宜乾糖漿劑。 本發明之製劑在經口用頭孢菌素配合糖醇及草莓香料爲 特徵,可將製劑處方通常使用之賦形劑、崩壞劑、結合劑 200404550 、矯味劑、甘味劑、著色劑、懸浮化劑、pH調節劑、消泡 劑、防腐劑、著香劑、香料、流動化劑、溶劑、水等適宜 地配合,依業者周知之方法,例如日本藥局方製劑總則或 仿此方法容易製造。 賦形劑可用乳糖、結晶纖維素、玉米澱粉、白糖等。 崩壞劑可用羧甲基澱粉鈉、羧甲醚纖維素、羧甲醚纖維 素鈣、羧甲醚纖維素鈉、聚乙烯聚吡咯啶酮、低置換度羥 丙基纖維素、部分α化澱粉、玉米澱粉等。 結合劑可用α化澱粉、乙基纖維素、聚乙烯吡咯啶酮、馨 共聚乙烯吡略啶酮、羥丙基纖維素、羥丙基甲基纖維素、 聚乙烯吡咯啶酮等。 矯味劑可用L -天冬胺酸酸鹽、肌胺酸、甘草、L _麩胺酸 、L -魅胺酸鈉、氯化鈉、甘草酸等。 甘味劑可用阿斯巴甜、甘草酸鹽、白糖、果糖、精精等。 著色劑可用黃色三二氧化鐡、焦糖、氧化鈦、三二氧化 鐵、葉綠素銅、核黃素等。 懸浮化劑可用羧甲醚纖維素鈉、藻酸鈉、甲基纖維素、魯 聚山梨酸酯8 0、黃耆膠末、鹿角菜膠、三仙膠等。 pH調節劑可用碳酸鈉、檸檬酸、丁二酸、酒石酸、碳酸 氫鈉、馬來酸、檸檬酸酐等。 消泡劑可用乙醇、三油酸山梨醇酯、聚山梨酸酯8 〇、蔗 糖脂肪酸酯等。 防腐劑司用苯甲酸、苯甲酸鈉、過氧苯甲酸醋等。 著香劑·香料可用桔精油、桔油、櫻桃香素、松油、水 果香素、檸檬香粉等。 -9 - 200404550 流動化劑可用輕質矽酸肝、硬脂酸、硬酯酸鎂、硬脂酸 鈣、滑石粉等。 溶劑可用乙醇、精製水、注射用水等。 (實施方式) 本發明之乾糖漿劑可在頭孢菌素化合物、糖醇及草莓香 料加上述賦形劑、崩壞劑、結合劑、矯味劑、著色劑、消 泡劑、pH調節劑、甘味劑等,混合後,邊噴霧結合劑溶液 邊施行流動層造粒而乾燥後,施行分級、整粒。所得顆粒 必要時加顆粒外成分,混合來製造。 (實施例1 )配合D -甘露糖醇與草莓香料之乾糖漿劑處方 每1服用量之重量(mg) 5 0 m g力價 27.18 3 0 10 5 25 20200404550 (1) Description of the invention: (Technical field) The present invention relates to an oral cephalosporin preparation for improving bitterness. (Prior art) As a method for improving the bitterness of a drug, a method of compounding sugars, artificial sweeteners, sugar alcohols, sour agents, amino acids, glutamates, and flavors is known. However, depending on the chemical structure of the drug, the type of bitterness also changes. Therefore, it is not easy to find a prescription for the optimal improvement of the inherent bitterness of the drug. Cephalosporin compounds for oral use (especially the ester prodrug type cephalosporins) have a strong bitterness unique to their compound groups. Preparations that are sensitive to bitterness by dispersing drugs such as dry syrup in the oral cavity are formulated to improve the bitterness in order to make it easier to take. (Summary of the Invention) The inventors have repeatedly reviewed the bitterness improvement of oral cephalosporins for many years. The combination of sugar alcohol and strawberry flavor showed a particularly excellent bitterness improvement effect than before, and finally completed the present invention. The present invention is an oral cephalosporin preparation for improving bitterness as follows. (1) An oral cephalosporin preparation is characterized by containing sugar alcohol and strawberry flavor. (2) If (1) the oral cephalosporin preparation, wherein the oral cephalosporin is an ester prodrug type cephalosporin ° (3) If (1) the oral cephalosporin preparation 'wherein Oral cephalosporins are selected from the group consisting of Cefpodoxime proxetil, Cefotiam Hexetil, and Chevrolet Bieber-6-200404550 Cefteram Pivoxil, Cefuroxime Acetil, Ceferetaniet Pivoxil, Cefditoren West Road Pivoxil) and Cefcapene Pivoxil (U.S.) were prepared orally using cephalosporins. (4) The cephalosporin preparation for oral use as described in (1), wherein the cephalosporin for oral use is Shefportic Simeon Prokaryostasis. (5) The cephalosporin preparation for oral use according to any one of (1) to (4), wherein the sugar alcohol is selected from the group consisting of erythritol, xylitol, mannitol and sorbitol. (6) The cephalosporin preparation for oral use according to any one of (1) to (4), wherein the sugar alcohol is D-mannitol. (7) The oral cephalosporin preparation according to any one of (1) to (6), wherein the preparation is selected from the group consisting of a dry syrup, a chewable tablet, an orally disintegrating tablet, a tongue tablet, a powder, and Granules. (8) The cephalosporin preparation for oral use according to any one of (1) to (6), wherein the preparation is a dry syrup. (9) The cephalosporin preparation for oral use according to (1), wherein the preparation is a dry syrup containing D-mannitol and strawberry flavor. (10) The cephalosporin preparation for oral use as described in (1), wherein the preparation is a dry syrup preparation containing D-mannitol and strawberry flavor, which is characterized by Chevrolet's Cixi Prometheus blood serum. The sugar alcohol used in the present invention is not particularly limited as long as it is a polyvalent alcohol whose carbonyl group is reduced, such as erythritol, xylitol, mannitol, and sorbitol. Chase some Zhongyi mannitol, the most suitable is D_mannitol. 200404550 The compounding amount of sugar alcohol in oral cephalosporin preparations is usually preferably 20 to 80% by weight, and most preferably 30 to 60% by weight. When D-mannitol is used, it is preferred that the weight of the strawberry flavor used in the present invention is, for example, strawberry particles, strawberry fragrant, strawberry powder, and strawberry flavor, and strawberry fragrant strawberry particles are preferred. The blending amount of strawberry flavor in oral cephalosporin preparations is generally preferably 0.001 to 5% by weight, and most preferably 0.05 to 2% by weight. When strawberry fragrant is used, it is preferably 0.05 to 0.1% by weight. The cephalosporin for oral use used in the present invention is not specific as long as it is an effective beta compound for oral administration, and an ester prodrug type cephalosporin with a 4-carboxyl group protected by an ester is preferred. The cephalosporin ester prodrugs may be, for example, Chevrolet Potchiximum Pro-stage Blood Gypsy, Xuefuqi Amu Black-phase Blood Gypsy, Chevron Tiram Bieber Stage West Road, Chevroch Ximu Ah Kuo Xue Ji, Shepherd also has Delta Dobberth West Road, Shepherds Dorian Bieber Road West and Shef Cabin Bieber Road West, the most suitable is Shepherd's Potsy Simeon Proton Blood Kyrgyzstan. The amount of the oral cephalosporin in the oral cephalosporin preparation is usually preferably 5 to 40% by weight, and most preferably 5 to 15% by weight. When using Shepherd's Potsy® Female Provencal Blood Gyro, it is optimally 5 to 10% by weight. The preparations applicable to the present invention are not specific as long as they are administered orally, and are suitable for preparations in which the drug is dispersed in the oral cavity and are susceptible to bitter taste, such as dry syrups, chewable tablets, orally disintegrating tablets, tongue tablets, Powder or granules. Especially dry syrup. The preparation of the present invention is characterized by oral cephalosporin combined with sugar alcohol and strawberry flavor. It can use excipients, disintegrating agents, binding agents 200404550, flavoring agents, sweeteners, coloring agents, suspensions commonly used in formulations. Agents, pH adjusters, antifoaming agents, preservatives, flavoring agents, perfumes, fluidizers, solvents, water, etc. are suitably blended according to methods well known to the industry, such as the general prescription of the Japanese Pharmacy or the like . As the excipient, lactose, crystalline cellulose, corn starch, sugar, and the like can be used. The disintegrating agents can be sodium carboxymethyl starch, carboxymethyl ether cellulose, carboxymethyl ether cellulose calcium, carboxymethyl ether sodium, polyvinylpolypyrrolidone, low-substitution hydroxypropyl cellulose, and partially alpha starch. , Corn starch, etc. As the binding agent, α-starch, ethyl cellulose, polyvinylpyrrolidone, copolyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinylpyrrolidone and the like can be used. As the flavoring agent, L-aspartate, sarcosinate, glycyrrhizin, L_glutamate, sodium L-melamine, sodium chloride, glycyrrhizin, and the like can be used. As the sweetener, aspartame, glycyrrhizinate, white sugar, fructose, refined essence and the like can be used. Examples of the colorant include yellow osmium trioxide, caramel, titanium oxide, iron trioxide, copper chlorophyll, riboflavin, and the like. As the suspending agent, sodium carboxymethylcellulose, sodium alginate, methylcellulose, Lu polysorbate 80, tragacanth gum, carrageenan, Sanxian gum and the like can be used. As the pH adjusting agent, sodium carbonate, citric acid, succinic acid, tartaric acid, sodium bicarbonate, maleic acid, citric anhydride and the like can be used. As the defoaming agent, ethanol, sorbitol trioleate, polysorbate 80, sucrose fatty acid ester and the like can be used. Preservatives use benzoic acid, sodium benzoate, peroxybenzoate, and so on. Perfumes and fragrances include orange essential oil, orange oil, cherry flavor, pine oil, pectin, lemon powder, and the like. -9-200404550 As the fluidizer, light-weight liver silicate, stearic acid, magnesium stearate, calcium stearate, talc, etc. can be used. The solvent can be ethanol, purified water, water for injection and the like. (Embodiment) The dry syrup of the present invention can be added to the cephalosporin compound, sugar alcohol and strawberry flavor with the above-mentioned excipients, disintegrating agents, binding agents, flavoring agents, coloring agents, antifoaming agents, pH adjusting agents, sweetness After mixing the agent, etc., the fluidized layer is granulated while spraying the binder solution and dried, and then classified and granulated. The obtained granules are produced by adding extra-granular components and mixing if necessary. (Example 1) Formulation of dry syrup with D-mannitol and strawberry flavor Weight per mg (mg) 5 0 m g Force value 27.18 3 0 10 5 25 20
20 5 3 80 3 92.4 5 10 雪芙波特奇西母普羅期血吉 乳糖 羧甲醚纖維素鈣 羥丙基纖維素 氯化鈉 麩胺酸鈉 阿斯巴甜 三二氧化鐵 羧甲醚纖維素鈉 檸檬酸(無水) D -甘露糖醇 白糖 三油酸山梨醇酯 苯甲酸鈉 草莓香素 滑石粉 輕質矽酸酐 _ 合計 -10、 200404550 (實施例2)配合D-甘露糖醇與草莓香微粒之乾糖漿劑處方(1) 每1服用量之重量(mg) 雪芙波特奇西母普羅期血吉 50mg力價 乳糖 13.15 羧甲醚纖維素鈣 30 羥丙基纖維素 10 氯化鈉 5 麩胺酸鈉 25 阿斯巴甜 20 三二氧化鐵 0.2 羧甲醚纖維素鈉 20 檸檬酸(無水) 5 D-甘露糖醇 3 80 白糖 3 92.4 三油酸山梨醇酯 5 苯甲酸鈉 10 草莓微粒 15 滑石粉 1 輕質矽酸酐 3 合計 1 0 0 0 m g 200404550 (實施例3)配合D-甘露糖醇與草莓香微粒之乾糖漿劑處方(2) 每1服用量之重量(mg) 雪芙波特奇西母普羅 乳糖 羧甲醚纖維素鈣 羥丙基纖維素 氯化鈉 麩胺酸鈉 阿斯巴甜 三二氧化鐵 羧甲醚纖維素鈉 檸檬酸(無水) D -甘露糖醇 白糖 三油酸山梨醇酯 苯甲酸鈉 草莓微粒 滑石粉 輕質矽酸酐_ 合計 期血吉 5 0 m g力價 13.15 3 0 10 5 25 20 0.2 20 5 5 00 2 72.4 5 10 15 1 3 1 0 0 0 m g20 5 3 80 3 92.4 5 10 Shepherd's Cixi Promum Blood Gelatose Carboxymethyl Carboxylate Cellulose Calcium Hydroxypropyl Cellulose Sodium Branate Sodium Aspartame Ferric Oxide Carboxymethyl Ether Fiber Sodium citric acid (anhydrous) D-mannitol white sugar trioleate sorbitol sodium benzoate strawberry vanillin talc powder light silicic anhydride _ Total -10, 200404550 (Example 2) Blended with D-mannitol and strawberry flavor Prescription of dry syrup of microparticles (1) Weight per 1 dose (mg) Shepherd's Pot Cixi Promethoxone 50mg Lipolactose 13.15 Carboxymethylcellulose calcium 30 Hydroxypropyl cellulose 10 Sodium chloride 5 Sodium glutamate 25 Aspartame 20 Ferric trioxide 0.2 Sodium carboxymethyl ether cellulose 20 Citric acid (anhydrous) 5 D-mannitol 3 80 White sugar 3 92.4 Sorbitol trioleate 5 Sodium benzoate 10 Strawberry Microparticles 15 Talc powder 1 Light silicic acid anhydride 3 Total 1 0 0 0 mg 200404550 (Example 3) Formulation of dry syrup with D-mannitol and strawberry aroma particles (2) Weight per mg (mg) Snow Fupotchixi Promethalactose Carboxymethyl Ether Cellulose Calcium Hydroxypropyl Cellulose Chloride Sodium glutamate, aspartame, ferric oxide, carboxymethylcellulose sodium, citric acid (anhydrous), D-mannitol, sugar, sorbitol trioleate, sodium benzoate, strawberry particles, talcum powder, light silicic acid _ Total blood Ji 5 0 mg power price 13.15 3 0 10 5 25 20 0.2 20 5 5 00 2 72.4 5 10 15 1 3 1 0 0 0 mg
-12- 200404550 (參考例1)配合桔微粒之乾糖漿劑處方 每1服用量之重量(mg) 雪芙波特奇西母普羅期血吉 5 Omg 力 乳糖 13.17 羧甲醚纖維素鈣 3 0 羥丙基纖維素 7.5 氯化鈉 5 鍵胺酸鈉 25 阿斯巴甜 25 三二氧化鐵 0. 1 羧甲醚纖維素鈉 20 檸檬酸(無水) 5 白糖 7 6 5.0 三油酸山梨醇酯 5 苯甲酸鈉 10 桔微粒 20 滑石粉 1 輕質矽酸酐 3 合計 1 0 0 0 m g-12- 200404550 (Reference Example 1) Weight per mg of dry syrup formulation with orange microparticles (mg) Shepherd's Potassium, Simeon Pro-stage Blood Gypsum 5 Omg, Lactose 13.17 Carboxymethyl Cellulose Calcium 3 0 Hydroxypropyl cellulose 7.5 Sodium chloride 5 Bonded sodium amine 25 Aspartame 25 Iron dioxide 0.1 Carboxymethyl cellulose sodium 20 Citric acid (anhydrous) 5 White sugar 7 6 5.0 Sorbitol trioleate 5 Sodium benzoate 10 Orange particles 20 Talc powder 1 Light silicic acid anhydride 3 Total 1 0 0 0 mg
200404550 (參考例2)配合D-甘露糖醇與桔微粒之乾糖漿劑處方 每1服用量之重量(mg) 雪芙波特奇西母普羅期血吉 50mg力價 乳糖 13.15 羧甲醚纖維素鈣 30 羥丙基纖維素 10 氯化鈉 5 麩胺酸鈉 25 阿斯巴甜 20 三二氧化鐵 0.2 羧甲醚纖維素鈉 2 0200404550 (Reference Example 2) Formulation of dry syrup containing D-mannitol and orange granules, weight per dose (mg) Chevrolet Portcixi Promethoxine 50mg potency lactose 13.15 carboxymethyl ether cellulose Calcium 30 Hydroxypropyl cellulose 10 Sodium chloride 5 Sodium glutamate 25 Aspartame 20 Iron trioxide 0.2 Sodium carboxymethyl cellulose 2 0
檸檬酸(無水) 5 D-甘露糖醇 380 白糖 3 9 2.4 三油酸山梨醇酯 5 苯甲酸鈉 10Citric acid (anhydrous) 5 D-mannitol 380 White sugar 3 9 2.4 Sorbitol trioleate 5 Sodium benzoate 10
桔微粒 20 滑石粉’ 1 輕質矽酸酐_3 合計 1 0 0 5 m g (試驗例1)苦味之比較試驗 就實施例1、實施例2、參考例1及參考例2之製劑,以 3 8名健常人(男2 1名,女1 7名)爲對象,施行試驗1〜3之 味評價試驗。將雪芙波特奇西母普羅期血吉50mg力價之製 -14- 200404550 劑含在口’俟崩壞後評價苦味之改善度。 試驗1 ·貫施例1與實施例2之比較(草莓香料彼此比較) 試驗2 :參考例1與參考例2之比較(桔香料彼此比較) S式驗3 · g 1與試驗2之勝者之比較(草莓香料與桔香 料之比較) (試驗1之結果) 實施例1較佳或稍佳 〗8名 實施例2較佳或稍佳 17名Orange granules 20 talc powder 1 Light silicic acid anhydride_3 Total 1 0 5 mg (Test Example 1) Comparative test of bitterness For the preparations of Example 1, Example 2, Reference Example 1 and Reference Example 2, 3 8 For healthy people (21 males and 17 females), the evaluation test of taste 1 to 3 was performed. The preparation of Chevrolet Potassium Simeon Pro-stage Blood Gypsum 50mg Power Formula -14-200404550 was included in the mouth ’s crumble to evaluate the degree of improvement of bitterness. Test 1 · Comparison of Example 1 and Example 2 (strawberry flavor comparison with each other) Test 2: Comparison of Reference Example 1 and Reference Example 2 (comparison of orange flavor with each other) S-type test 3 · g 1 and winner of Test 2 Comparison (comparison between strawberry flavor and orange flavor) (Result of test 1) Example 1 is better or slightly better〗 8 examples 2 are better or slightly better 17
無法評判 3名 (試驗2之結果) 參考例1較佳或稍佳 1名 參考例2較佳或梢佳 3 5名 無法評判 2名 (試驗3之結果) 草莓味較佳 2 1名 桔味較佳 1 4名Cannot judge 3 (result of test 2) Reference example 1 is better or slightly better 1 reference example 2 is better or better 3 5 cannot be judged 2 (result of test 3) strawberry taste is better 2 1 orange Better 1 4
無法評判 3名 由試驗1之結果得知,就配合D -甘露糖醇之製劑彼此, 在草莓香素製劑與草莓微粒製劑其味同等。由試驗2之結 果得知,在桔微粒製劑配合D _甘露糖醇之製劑較未配合D _ 甘露糖醇之製劑其味較佳。由試驗3之結果得知,配合D -甘露糖醇之製劑彼此也草莓味比桔味爲佳。結論爲配合D-甘露糖醇與草莓香料使雪芙波特奇西母普羅期血吉製劑之 苦味格外改善。 -15- 200404550 (產業上利用可能性) 在經口用頭孢菌素製劑(尤其含有酯前藥型頭孢菌素之 乾糖漿劑)配合糖醇(尤其D-甘露糖醇)與草莓香料,發現比 從來之處方有格外優異之苦味改善效果。 (圖式簡單說明)無Unable to judge 3 people From the results of Test 1, it was found that the formulations containing D-mannitol had the same flavor in the strawberry fragrant preparation and the strawberry fine particle preparation. From the results of Test 2, it is known that the formulation containing D_mannitol in the orange particle preparation has a better taste than the formulation without D_mannitol. From the results of Test 3, it was found that the formulations containing D-mannitol had better strawberry flavor than orange flavor. CONCLUSION: The combination of D-mannitol and strawberry flavor can improve the bitterness of Chevrolet's Cixi Promethoxine preparation. -15- 200404550 (Possibility of industrial utilization) Oral use of cephalosporin preparations (especially dry syrup containing ester prodrug type cephalosporins) combined with sugar alcohol (especially D-mannitol) and strawberry flavor, found It has an exceptionally better bitterness improvement effect than ever before. (Schematic description) None
-16--16-
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002198464 | 2002-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200404550A true TW200404550A (en) | 2004-04-01 |
Family
ID=30112427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092118481A TW200404550A (en) | 2002-07-08 | 2003-07-07 | Cepharospolin formulation for oral use |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003281268A1 (en) |
TW (1) | TW200404550A (en) |
WO (1) | WO2004004737A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006022420A1 (en) | 2004-08-25 | 2006-03-02 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
US20070134277A1 (en) * | 2005-12-09 | 2007-06-14 | Children's Medical Center Corporation | Pharmaceutical formulation for sulfur-containing drugs in liquid dosage forms |
EP2566451B1 (en) * | 2010-05-04 | 2014-09-10 | Mahmut Bilgic | Pharmaceutical compositions comprising cefditoren pivoxil |
CN102370621A (en) * | 2010-08-19 | 2012-03-14 | 北京润德康医药技术有限公司 | Solid preparation with cefotiam hexetil as active component |
TR201007106A1 (en) * | 2010-08-25 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Cefpodoxime proxetil formulations. |
TR201007107A1 (en) * | 2010-08-25 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Formulations of cefpodoxime proxetil containing taste regulating agent. |
TR201009168A2 (en) * | 2010-11-05 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Water dispersible cefpodoxime proxetil formulations. |
CN103479589B (en) * | 2013-09-22 | 2016-04-13 | 海南葫芦娃制药有限公司 | cefpodoxime proxetil dispersible tablet and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4418957A1 (en) * | 1994-05-31 | 1995-12-07 | Merck Patent Gmbh | Cefixime preparation |
ES2079327B1 (en) * | 1994-12-13 | 1996-08-01 | Lilly Sa | PHARMACEUTICAL FORMULATIONS OF CEFACLOR. |
NZ330864A (en) * | 1996-02-29 | 2001-07-27 | Fujisawa Pharmaceutical Co | Beta-lactam antibiotic-containing tablet including a disintegrant and a binder |
US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
AT413647B (en) * | 1998-11-26 | 2006-04-15 | Sandoz Ag | USE OF A COPOLYMERISATE OF 1-VINYL-2-PYRROLIDONE AND VINYL ACETATE FOR THE PREPARATION OF CEFUROXIMAXETIL-SUBJECTED TABLETS |
AT500063A1 (en) * | 1999-11-23 | 2005-10-15 | Sandoz Ag | COATED TABLETS |
-
2003
- 2003-07-07 TW TW092118481A patent/TW200404550A/en unknown
- 2003-07-08 AU AU2003281268A patent/AU2003281268A1/en not_active Abandoned
- 2003-07-08 WO PCT/JP2003/008673 patent/WO2004004737A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2003281268A1 (en) | 2004-01-23 |
WO2004004737A1 (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2184570C2 (en) | Preparations for oral administration | |
AU609988B2 (en) | Pharmaceutical compositions | |
TWI376243B (en) | Oral disintegrating tablet | |
AU2002302147B2 (en) | Pharmaceutical composition | |
JP5859664B2 (en) | Oral pharmaceutical composition with masked taste of drug and method for producing the same | |
JPH09508402A (en) | Oral liquid composition containing paroxetine-resin | |
CA2429650A1 (en) | Oral pharmaceutical compositions containing cyclodextrins as taste masking agent | |
JP5566408B2 (en) | Dry syrup | |
TW200404550A (en) | Cepharospolin formulation for oral use | |
JP2007517864A (en) | Cefuroxime axetil granules and method for producing the same | |
JP4526247B2 (en) | Oral cephalosporins | |
CA2477773C (en) | A stable diclofenac-tromethamine composition for the topical treatment of oropharyngeal cavity disorders | |
JP3899522B2 (en) | Formulation containing pranlukast hydrate with reduced bitterness | |
US10016359B2 (en) | Solid forms containing meloxicam with improved buccal taste and process for their preparation | |
JP2006131625A (en) | Isosorbid preparation improved in taste quality | |
CN114681616A (en) | Fexofenadine hydrochloride dry suspension and preparation method thereof | |
JPH10203963A (en) | Orally administrable pharmaceutical composition containing microbicidal material and mucosa-adhesive material | |
US9211265B2 (en) | Tablets comprising a taste masking agent | |
KR20040079012A (en) | Acetylcysteine oral dosage forms | |
WO1999041233A1 (en) | A watersoluble nimesulide adduct also for injectable use | |
ES2303468B1 (en) | "A PULVERULENT PHARMACEUTICAL COMPOSITION THAT INCLUDES IBUPROFEN". | |
JP2001253826A (en) | Internal medicine | |
EP1154775B1 (en) | Therapeutic aqueous composition containing a hexahydro-5-pyrimidinamine compound and a polyalkoxylated fatty alcohol | |
CN111787906A (en) | Oral dosage form containing theobromine-free cocoa | |
JP2006316051A (en) | Pranlukast hydrate-containing preparation having relieved bitterness |